University of Queensland spin-off company Coridon Pty Ltd has received ethical approval to commence a Phase I clinical trial in Brisbane. The Coridon HSV-2 Vaccine targets genital herpes infection – a major unmet medical need.
Professor Ian Frazer is developing the first in class vaccine for HSV-2 genital herpes, which affects up to 1 in 8 Australians, and for which there is currently no curative treatment. The vaccine technology utilises a patented optimisation technology that offers the potential of being both a preventative and therapeutic vaccine.
The vaccine will be administered via intradermal injection into the forearms of twenty healthy volunteers. The outcomes of the Phase I trial will demonstrate the vaccine’s safety and how well tolerated it is, as well as determining the effective dose and showing that the vaccine generates a robust immune response.
“This is the beginning of an exciting period for our herpes vaccine. We have seen very encouraging results from animal studies and we expect pivotal data showing that our vaccine, which incorporates our patented optimisation technology, to produce similar immune responses in the clinic,” said Professor Frazer.
The Phase I clinical trial will be undertaken through Q-Pharm Pty Ltd’s clinical trial site based at the Royal Brisbane and Women’s Hospital. Manager of Medical Services at Q-Pharm and the Principal Investigator for the study is Dr. Paul Griffin FRACP, FRCPA, MBBS, an experienced infectious diseases physician and microbiologist. He is also the Director of Infectious Diseases at Mater Health Services, a major hospital in Brisbane and a Senior Lecturer at the University of Queensland.
We are seeking healthy male and female volunteers, aged 18-45 years, who may be interested in participating in a clinical trial of an investigational vaccine for herpes infection and have never had a cold sore. Recruitment of volunteers is expected to start in July and dosing of subjects in the clinical trial to commence in August/ September this year.